Mostrar o rexistro simple do ítem

Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases

dc.contributor.authorCustodia Malvido, Antía
dc.contributor.authorRomaus Sanjurjo, Daniel
dc.contributor.authorAramburu Nuñez, Marta
dc.contributor.authorÁlvarez-Rafael, D.
dc.contributor.authorVázquez-Vázquez, L.
dc.contributor.authorCamino Castiñeiras, Javier
dc.contributor.authorLeira Feijoo, Yago
dc.contributor.authorPías-Peleteiro, J.M.
dc.contributor.authorAldrey, J.M.
dc.contributor.authorSobrino Moreiras, Tomas 
dc.contributor.authorOuro Villasante, Alberto
dc.date.accessioned2025-08-26T08:49:39Z
dc.date.available2025-08-26T08:49:39Z
dc.date.issued2022
dc.identifier.citationCustodia A, Romaus-Sanjurjo D, Aramburu-Núñez M, Álvarez-Rafael D, Vázquez-Vázquez L, Camino-Castiñeiras J, et al. Ceramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases. International journal of molecular sciences. NLM (Medline); 2022;23(15).
dc.identifier.issn1422-0067
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/630aa0ec1d67d450646ae83e*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20620
dc.description.abstractAlzheimer's disease (AD) is considered the most prevalent neurodegenerative disease and the leading cause of dementia worldwide. Sphingolipids, such as ceramide or sphingosine 1-phosphate, are bioactive molecules implicated in structural and signaling functions. Metabolic dysfunction in the highly conserved pathways to produce sphingolipids may lead to or be a consequence of an underlying disease. Recent studies on transcriptomics and sphingolipidomics have observed alterations in sphingolipid metabolism of both enzymes and metabolites involved in their synthesis in several neurodegenerative diseases, including AD. In this review, we highlight the most relevant findings related to ceramide and neurodegeneration, with a special focus on AD.en
dc.description.sponsorshipThis review was partially supported by grants from the Xunta de Galicia (T.S.: IN607D 2020/09, A.C.: IN606A-2021/015, and D.R.-S.: IN606B-2021/010), and Science Ministry of Spain (T.S.: RTI2018-102165-B-I00, T.S.: RTC2019-007373-1). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (T.S.: EAPA_791/2018_ NEUROATLANTIC project), INTER-REG V A Espana Portugal (POCTEP) (T.S.: 0624_2IQBIONEURO_6_E), and the European Regional Development Fund (ERDF). Moreover, D.R.-S. (CD21/00166) and M.A.-N. (IFI18/00008) are recipients of Sara Borrell and iPFIS contracts from Instituto de Salud Carlos III, respectively. Finally, TS (CPII17/00027) is recipient of a research contract from the Miguel Servet Program from the Instituto de Salud Carlos III. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleCeramide/Sphingosine 1-Phosphate Axis as a Key Target for Diagnosis and Treatment in Alzheimer's Disease and Other Neurodegenerative Diseases*
dc.typeReviewen
dc.authorsophosCustodia, A. A.
dc.authorsophosRomaus-Sanjurjo, D.
dc.authorsophosAramburu-Núñez, M.
dc.authorsophosÁlvarez-Rafael, D.
dc.authorsophosVázquez-Vázquez, L.
dc.authorsophosCamino-Castiñeiras, J.
dc.authorsophosLeira, Y.
dc.authorsophosPías-Peleteiro, J. M.
dc.authorsophosAldrey, J. M.
dc.authorsophosSobrino, T.
dc.authorsophosOuro
dc.identifier.doi10.3390/ijms23158082
dc.identifier.sophos630aa0ec1d67d450646ae83e
dc.issue.number15
dc.journal.titleInternational journal of molecular sciences*
dc.relation.projectIDXunta de Galicia [IN607D 2020/09, IN606A-2021/015, IN606B-2021/010]; Science Ministry of Spain [RTI2018-102165-B-I00, RTC2019-007373-1]; INTERREG Atlantic Area [EAPA_791/2018_ NEUROATLANTIC]; INTER-REG V A Espana Portugal (POCTEP) [0624_2IQBIONEURO_6_E]; European Regional Development Fund (ERDF); Instituto de Salud Carlos III [CD21/00166, IFI18/00008]; Miguel Servet Program from the Instituto de Salud Carlos III [CPII17/00027]
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/23/15/8082/pdf?version=1658830631;https://mdpi-res.com/d_attachment/ijms/ijms-23-08082/article_deploy/ijms-23-08082-v2.pdf?version=1658830631es
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordIDISes
dc.subject.keywordCHUSes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo de Revisiónes
dc.volume.number23


Ficheiros no ítem

Descargar/
Nome:
533.pdf
Tamaño:
1.260Mb
Formato:
PDF
Descrición:
Custodia A, Romaus-Sanjurjo D, Aramburu-Núñez M, Álvarez-Rafael D, Vázquez-Vázquez ...

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional